IonQ, in partnership with AstraZeneca, AWS, and NVIDIA Achieve Major Quantum Breakthrough in Drug Development

• 20x speedup in simulating a key pharmaceutical reaction using a quantum-classical hybrid workflow.
• Collaboration between IonQ, AstraZeneca, AWS, and NVIDIA significantly shortens early-stage drug development.
• Suzuki-Miyaura reaction modeled faster and more accurately — from months to days.
• Proof of concept for quantum-accelerated drug discovery to improve time-to-market and R&D efficiency.
• Showcased at ISC High Performance 2025 in Hamburg, Germany.

IonQ (IONQ.US), in partnership with AstraZeneca, AWS, and NVIDIA, has announced a significant leap in quantum-accelerated computational chemistry. The companies jointly developed and demonstrated a hybrid quantum-classical workflow that achieved over 20x faster simulation times for the Suzuki-Miyaura reaction, a crucial step in small-molecule drug synthesis.

The breakthrough integrates IonQ’s Forte quantum processor, NVIDIA’s CUDA-Q platform, and AWS cloud infrastructure. By combining quantum and GPU resources on AWS through Amazon Braket and ParallelCluster, the team cut simulation time from months to days without compromising accuracy.

This advance showcases how quantum-enhanced computing can solve previously intractable problems in early-stage pharmaceutical R&D, reducing costs and accelerating timelines — a competitive advantage in a $100B+ drug development industry.

IonQ emphasized that this demonstration, the most complex chemical simulation ever run on its hardware, proves the scalability and commercial utility of hybrid quantum-classical solutions. The company believes this lays the groundwork for broader applications in healthcare, chemistry, and materials science.

IonQ is up 2.45% today, trading at $40.30 per share. Over the past year, the company has increased its market capitalization by as much as 470%.

The material on this page does not constitute financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other specific needs. All information provided, including opinions, market research, mathematical results and technical analyzes published on the Website or transmitted To you by other means, it is provided for information purposes only and should in no way be construed as an offer or solicitation for a transaction in any financial instrument, nor should the information provided be construed as advice of a legal or financial nature on which any investment decisions you make should be based exclusively To your level of understanding, investment objectives, financial situation, or other specific needs, any decision to act on the information published on the Website or sent to you by other means is entirely at your own risk if you In doubt or unsure about your understanding of a particular product, instrument, service or transaction, you should seek professional or legal advice before trading. Investing in CFDs carries a high level of risk, as they are leveraged products and have small movements Often the market can result in much larger movements in the value of your investment, and this can work against you or in your favor. Please ensure you fully understand the risks involved, taking into account investments objectives and level of experience, before trading and, if necessary, seek independent advice.